WO1997032891B1 - Conjugate for modifying interactions between proteins - Google Patents
Conjugate for modifying interactions between proteinsInfo
- Publication number
- WO1997032891B1 WO1997032891B1 PCT/DE1997/000458 DE9700458W WO9732891B1 WO 1997032891 B1 WO1997032891 B1 WO 1997032891B1 DE 9700458 W DE9700458 W DE 9700458W WO 9732891 B1 WO9732891 B1 WO 9732891B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conjugate
- receptor
- polypeptides
- conjugate according
- linker
- Prior art date
Links
- 230000003993 interaction Effects 0.000 title claims abstract 3
- 102000004169 proteins and genes Human genes 0.000 title claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 3
- 229920001184 polypeptide Polymers 0.000 claims abstract 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 14
- 102000005962 receptors Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000003675 cytokine receptors Human genes 0.000 claims 3
- 108010057085 cytokine receptors Proteins 0.000 claims 3
- 239000013613 expression plasmid Substances 0.000 claims 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims 1
- 102000016989 Ciliary Neurotrophic Factor Receptor Human genes 0.000 claims 1
- 108010000063 Ciliary Neurotrophic Factor Receptor Proteins 0.000 claims 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
Abstract
The present invention concerns a conjugate comprising two polypeptides with a mutual affinity and connected via a linker. It also concerns the use of such a conjugate to modify interactions between proteins.
Claims
1 . Konjugat, umfassend zwei, eine Affinität zueinander aufweisende, Polypeptide, wobei die Polypeptide über einen Linker miteinander verbunden sind, dadurch gekennzeichnet, daß der Linker eine durch die zwei Polypeptide ausgebildete Disulfidbrücke oder ein Polypeptid ist.1 . A conjugate comprising two affinities with one another, wherein the polypeptides are linked together by a linker, characterized in that the linker is a disulfide bridge formed by the two polypeptides or a polypeptide.
2. Konjugat nach Anspruch 1 , dadurch gekennzeichnet, daß das eine Polypeptid ein Rezeptor und das andere ein den Rezeptor bindender Ligand ist.2. A conjugate according to claim 1, characterized in that the one polypeptide is a receptor and the other is a receptor binding ligand.
3. Konjugat nach Anspruch 2, dadurch gekennzeichnet, daß der Rezeptor in Form seiner den Liganden bindenden Untereinheit vorliegt.3. A conjugate according to claim 2, characterized in that the receptor is present in the form of its ligand binding subunit.
4. Konjugat nach Anspruch 2 oder 3, dadurch gekennzeichnet, daß der Ligand in Form semer den Rezeptor bindenden Untereinheit vorliegt.4. A conjugate according to claim 2 or 3, characterized in that the ligand is present in the form of semer receptor binding subunit.
5. Konjugat nach einem der Ansprüche 2-4, dadurch gekennzeichnet, daß der Rezeptor ein Zytokin-Rezeptor und der Ligand ein Zytokin ist.5. A conjugate according to any one of claims 2-4, characterized in that the receptor is a cytokine receptor and the ligand is a cytokine.
6. Konjugat nach Anspruch 5, dadurch gekennzeichnet, daß der Zytokm- Rezeptor ein IL-6 Rezeptor und das Zytokin ein IL-6 ist.6. A conjugate according to claim 5, characterized in that the cytokine receptor is an IL-6 receptor and the cytokine is an IL-6.
7. Konjugat nach Anspruch 5, dadurch gekennzeichnet, daß der Zytokin- Rezeptor ein CNTF-Rezeptor und das Zytokin ein CNTF ist.7. A conjugate according to claim 5, characterized in that the cytokine receptor is a CNTF receptor and the cytokine is a CNTF.
8. Konjugat nach einem der Ansprüche 1 - 7, dadurch gekennzeichnet, daß das Konjugat ein Fusionspolypeptid ist. - 14 -8. A conjugate according to any one of claims 1-7, characterized in that the conjugate is a fusion polypeptide. - 14 -
9. DNA, kodierend für das Konjugat nach Anspruch 8.9. DNA encoding the conjugate according to claim 8.
10. Expressionsplasmid, umfassend die DNA nach Anspruch 9.10. An expression plasmid comprising the DNA according to claim 9.
1 1 . Transformante, enthaltend das Expressionsplasmid nach Anspruch 10.1 1. A transformant containing the expression plasmid according to claim 10.
1 2. Verwendung des Konjugats nach einem der Ansprüche 1 - 8 und der DNA nach Anspruch 9 zur Beeinflussung der Wechselwirkungen zwischen Proteinen. 1 2. Use of the conjugate according to any one of claims 1-8 and the DNA according to claim 9 for influencing the interactions between proteins.
- 15 -- 15 -
IN ARTIKEL 19 GENANNTE ERKLÄRUNGDECLARATION REFERRED TO IN ARTICLE 19
I) Als Stand der Technik werden die folgenden Druckschriften genannt:I) The following publications are mentioned as prior art:
(D1 ) Stoyan et al., European Journal of Biochemistry, Bd.(D1) Stoyan et al., European Journal of Biochemistry, Vol.
21 6, Nr. 1 , S. 239-245 ( 1 993) (D2) Ehlers et al., Journal of Immunology, Bd. 1 53, Nr. 4, S.21 6, No. 1, pp. 239-245 (1 993) (D2) Ehlers et al., Journal of Immunology, Vol. 1 53, No. 4, p.
1 744-1 753 ( 1 994) (D3) WO-A-96/043141 744-1 753 (1 994) (D3) WO-A-96/04314
(D4) US-A-5 260 203(D4) US-A-5,260,203
(D5) WO-95/1 5341(D5) WO-95/1 5341
(D6) Sui et al. , Proceed. of the National Academy of(D6) Sui et al. , Proceed. of the National Academy of
Sciences USA, Bd. 92, S. 2859-2863 ( 1 995) (D7) Fischer et al., Nature Biotechnology, Bd. 1 5, Nr. 2, S.Sciences USA, Vol. 92, pp. 2859-2863 (1,995) (D7) Fischer et al., Nature Biotechnology, Vol. 1 5, No. 2, p.
142-145 (Febr. 1 997)142-145 (Feb. 1 997)
II) Der geänderte Anspruch 1 betrifft nun ein Konjugat, umfassend zwei, eine Affinität zueinander aufweisende Polypeptide, wobei die Polypeptide über einen Linker miteinander verbunden sind, dadurch gekennzeichnet, daß der Linker eine durch die zwei Polypeptide ausgebildete Disulfidbrücke oder ein Polypeptid ist.II) The amended claim 1 now relates to a conjugate comprising two polypeptides having affinity for one another, wherein the polypeptides are linked together by a linker, characterized in that the linker is a disulfide bridge formed by the two polypeptides or a polypeptide.
III) Gegenüber dem im Recherchenbericht genannten Stand der Technik ist der Gegenstand der vorliegenden Anmeldung neu und erfinderisch. In keiner der zahlreichen Entgegenhaltungen D1 -D6 ist ein Konjugat gezeigt oder nahegelegt, das zwei eine Affinität zueinander aufweisende Polypeptide umfaßt, wobei die Polypeptide über einen Linker miteinander verbunden sind und das dadurch gekennzeichnet ist, daß der Linker eine durch die zwei Polypeptide ausgebildete Disulfidbrücke oder ein Polypeptid ist. D7 stellt als P,X-Doku- ment keinen Stand der Technik dar, da von wirksamer Inanspruchnahme der Priorität ausgegangen wird. III) Compared with the prior art mentioned in the search report, the subject of the present application is novel and inventive. None of the numerous references D1-D6 disclose or suggest a conjugate comprising two affinity polypeptides, wherein the polypeptides are linked by a linker and characterized in that the linker forms a disulfide bridge formed by the two polypeptides is a polypeptide. D7 does not represent a state of the art as a P, X document, as it is assumed that the priority is being used effectively.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97919258A EP0888384B1 (en) | 1996-03-07 | 1997-03-07 | Fusion polypeptide for modifying interactions between proteins |
JP53135697A JP4301575B2 (en) | 1996-03-07 | 1997-03-07 | Conjugates to influence interactions between proteins |
US09/142,471 US7112436B1 (en) | 1996-03-07 | 1997-03-07 | Conjugate for modifying interactions between proteins |
DE59708952T DE59708952D1 (en) | 1996-03-07 | 1997-03-07 | FUSION POLYPEPTIDE FOR INFLUENCING INTERACTIONS BETWEEN PROTEINS |
DK97919258T DK0888384T3 (en) | 1996-03-07 | 1997-03-07 | Fusion polypeptide to influence interactions between proteins |
AT97919258T ATE229542T1 (en) | 1996-03-07 | 1997-03-07 | FUSION POLYPEPTIDE FOR INFLUENCING INTERACTIONS BETWEEN PROTEINS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19608813.5 | 1996-03-07 | ||
DE19608813A DE19608813C2 (en) | 1996-03-07 | 1996-03-07 | Conjugate for influencing interactions between proteins |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1997032891A2 WO1997032891A2 (en) | 1997-09-12 |
WO1997032891A3 WO1997032891A3 (en) | 1998-02-05 |
WO1997032891B1 true WO1997032891B1 (en) | 1998-03-19 |
Family
ID=7787490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1997/000458 WO1997032891A2 (en) | 1996-03-07 | 1997-03-07 | Conjugate for modifying interactions between proteins |
Country Status (9)
Country | Link |
---|---|
US (1) | US7112436B1 (en) |
EP (1) | EP0888384B1 (en) |
JP (1) | JP4301575B2 (en) |
AT (1) | ATE229542T1 (en) |
DE (2) | DE19608813C2 (en) |
DK (1) | DK0888384T3 (en) |
ES (1) | ES2188935T3 (en) |
PT (1) | PT888384E (en) |
WO (1) | WO1997032891A2 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6217858B1 (en) | 1997-02-11 | 2001-04-17 | Hadasit & Medical Research Services & Development Company, Ltd. | Pharmaceutical composition for treating hepatitis B virus (HBV) infection |
IL122818A0 (en) * | 1997-07-10 | 1998-08-16 | Yeda Res & Dev | Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof |
US7446183B2 (en) | 2000-06-16 | 2008-11-04 | Asterion Limited | Fusion protein comprising growth hormone and growth hormone receptor |
DE10107737A1 (en) * | 2001-02-16 | 2002-09-05 | S Rose John Christian Albrecht | Use of a conjugate of IL-6 and an IL-6 receptor for tumor therapy |
EP1499332A4 (en) * | 2002-04-29 | 2006-12-06 | Hadasit Med Res Service | Compositions and methods for treating cancer with an oncolytic viral agent |
EP1400587A1 (en) * | 2002-09-19 | 2004-03-24 | MainGen Biotechnologie GmbH | Use of a fusion polypeptide for obtaining pluripotent non-embryonic stem cells |
IL161672A0 (en) | 2004-04-29 | 2004-09-27 | Yeda Res & Dev | Compositions and methods for therapy of chemotherapy-induced neuropathy |
EP1598364A1 (en) * | 2004-05-21 | 2005-11-23 | AGIRx Limited | Chimerical soluble hyper IL-11 receptor and use thereof |
DE102004033122A1 (en) * | 2004-07-08 | 2006-02-09 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Apparatus and method for analyzing interactions between biomolecules |
PL1899364T5 (en) | 2005-05-17 | 2024-12-09 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
JP5266460B2 (en) * | 2005-06-16 | 2013-08-21 | ハダジット メディカル リサーチ サービシズ アンド ディベラップメント リミテッド | Methods for treating renal failure |
EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
CN102796743B (en) | 2006-01-13 | 2015-11-18 | 美国政府健康及人类服务部国立卫生研究院 | For codon optimized IL-15 and the IL-15R α gene of expressing in mammalian cell |
EP2415783B1 (en) | 2006-10-16 | 2016-12-14 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
ES2716476T3 (en) * | 2007-06-27 | 2019-06-12 | Us Health | IL15 and IL15Ralfa complexes and their uses |
CN101827857A (en) * | 2007-08-03 | 2010-09-08 | 埃斯特瑞恩有限公司 | Granulocyte colony stimulating factor |
GB0715213D0 (en) * | 2007-08-06 | 2007-09-12 | Asterlon Ltd | Igf-1 |
JP2011504924A (en) * | 2007-11-28 | 2011-02-17 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | Methods for the treatment of tissue damage induced by radiation or chemotherapy |
WO2009139921A2 (en) * | 2008-05-16 | 2009-11-19 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
WO2010081738A1 (en) * | 2009-01-16 | 2010-07-22 | Agirx Limited | Vaccine compositions |
CA2768965C (en) | 2009-08-14 | 2019-06-04 | George N. Pavlakis | Use of il-15 to increase thymic output and to treat lymphopenia |
WO2011151716A1 (en) | 2010-06-04 | 2011-12-08 | Lupin Limited | Process for the purification of recombinant human il-11 |
JP6280031B2 (en) | 2012-03-29 | 2018-02-14 | 中外製薬株式会社 | Anti-LAMP5 antibody and use thereof |
CN109395064A (en) | 2013-04-19 | 2019-03-01 | 赛腾制药 | The derivative treatment of the cell factor of reduced vascular leak syndrome |
EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
EP2992898A1 (en) | 2014-09-04 | 2016-03-09 | Klinikum rechts der Isar der Technischen Universität München | T-cell adjuvant and its use for therapeutic or prophylactic vaccination |
CN110055224B (en) * | 2019-04-03 | 2023-06-30 | 深圳市体内生物医药科技有限公司 | Genetically modified immune cell and preparation method and application thereof |
EP3875111A1 (en) | 2020-03-05 | 2021-09-08 | Poznan University Of Medical Sciences | Stem cell cancer vaccine composition |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
GB9324807D0 (en) * | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
ES2152424T5 (en) | 1994-07-29 | 2010-07-05 | Sunol Molecular Corporation | MHC COMPLEXES AND USES OF THE SAME. |
-
1996
- 1996-03-07 DE DE19608813A patent/DE19608813C2/en not_active Expired - Fee Related
-
1997
- 1997-03-07 WO PCT/DE1997/000458 patent/WO1997032891A2/en active IP Right Grant
- 1997-03-07 PT PT97919258T patent/PT888384E/en unknown
- 1997-03-07 AT AT97919258T patent/ATE229542T1/en active
- 1997-03-07 ES ES97919258T patent/ES2188935T3/en not_active Expired - Lifetime
- 1997-03-07 JP JP53135697A patent/JP4301575B2/en not_active Expired - Fee Related
- 1997-03-07 DE DE59708952T patent/DE59708952D1/en not_active Expired - Lifetime
- 1997-03-07 EP EP97919258A patent/EP0888384B1/en not_active Expired - Lifetime
- 1997-03-07 US US09/142,471 patent/US7112436B1/en not_active Expired - Fee Related
- 1997-03-07 DK DK97919258T patent/DK0888384T3/en active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997032891B1 (en) | Conjugate for modifying interactions between proteins | |
DE69233528T2 (en) | Process for the preparation of multivalent antigen-binding proteins | |
DE3785186T2 (en) | BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN. | |
EP0835934A3 (en) | Muteins of streptavidin | |
UA29494C2 (en) | Humanized antibodies, methods for producing thereof, a method for treatment of Crohns disease, a method for treatment OF disseminated sclerosis, pharmaceutical composition | |
AU1873199A (en) | Method of identifying binding site domains that retain the capacity of binding to an epitope | |
CA2155185A1 (en) | Totally synthetic affinity reagents | |
CA2081028A1 (en) | Cd2 binding domain of lymphocyte function associated antigen 3 | |
DE68916537D1 (en) | PRODUCTION OF AN INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN. | |
AU9052891A (en) | Proteins with changed epitopes and methods for the production thereof | |
KR950005324A (en) | Insulin preparations | |
NZ507879A (en) | Antibodies to CD23 capable of binding to the CD23 (FCepsilonRII) type II molecule expressed on haematopoietic cells | |
AU4162400A (en) | Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii | |
DE3855421D1 (en) | Modular assembly of antibody genes, antibodies produced thereby and their application | |
DE3382197D1 (en) | MUTEINE BIOLOGICALLY ACTIVE PROTEINS WITH REDUCED CYSTE CONTENT, THEIR PRODUCTION, FORMULATIONS THAT CONTAIN SUCH AS MUTEINE, AND STRUCTURAL GENES, VECTORS AND ORGANISMS THAT ARE SUITABLE FOR THE PRODUCTION OF THE MUTINE AND THEIR PRODUCTION. | |
NZ233642A (en) | Linked hemoglobin subunits, preparation by genetic engineering and linker assay | |
DE69535948D1 (en) | WDP-40 ABREGING PEPTIDES AND THEIR USE | |
WO1995030750A3 (en) | Lag-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody | |
CA2195076A1 (en) | Process for modifying the stability of antibodies | |
CA2299049A1 (en) | Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging | |
ATE140029T1 (en) | PRODUCTION OF BIOLOGICALLY ACTIVE INSULIN-LIKE GROWTH FACTOR I FROM HIGH EXPRESSION HOST CELL SYSTEMS | |
KR960701899A (en) | Protein Complexes Having Factor VIII: C Activity and Their Preparation | |
CA2006322A1 (en) | Recombinant dna molecules, hosts, processes and human somatomedin carrier protein-like polypeptides | |
CA2075974A1 (en) | Totally synthetic affinity reagents | |
CA2019671A1 (en) | Oxidative denaturation of protein analytes |